Diligence memo · auto-generated · as of July 2, 2026
Ansa Biotechnologies, Inc.
Ansa Biotechnologies, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Ansa Biotechnologies, Inc. operates in Biotechnology, based in EMERYVILLE, CA, USA. Next-generation DNA synthesis using enzymes
Sub-sector tags: biotech, medical-devices, pharma.
Capital & rounds (filed)filed
Ansa Biotechnologies, Inc. has raised $124M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $68M on 2022-03-18.
Most recent recorded round closed around 2024-06-28.
Valuation (modeled)modeled
Provath models Ansa Biotechnologies, Inc. at approximately $416M (range $144M–$632M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 1.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotechnology peers (4293 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.